Management of Borderline Resectable Pancreatic Cancer

被引:49
|
作者
Katz, Matthew H. G. [1 ]
Crane, Christopher H. [2 ]
Varadhachary, Gauri [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
关键词
GEMCITABINE-BASED CHEMORADIATION; EXPERT CONSENSUS STATEMENT; PREOPERATIVE GEMCITABINE; RADIATION-THERAPY; MULTIINSTITUTIONAL PHASE-2; NEOADJUVANT GEMCITABINE; CONTROLLED-TRIAL; DOSE-ESCALATION; ADENOCARCINOMA; CHEMOTHERAPY;
D O I
10.1016/j.semradonc.2013.11.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Borderline resectable pancreatic cancers are those that, although technically resectable, are at high risk for margin-positive resection following surgery de novo. Generally, such cancers are characterized by localized primary tumors that involve the mesenteric vasculature to a limited degree and that may require venous or hepatic arterial resection at pancreatectomy. In this article, we review diagnosis and staging algorithms, pretreatment strategies, and multidisciplinary treatment protocols for patients with this stage of disease. The rationale for and results following treatment with neoadjuvant chemotherapy and chemoradiation and subsequent surgical resection of the primary tumor are described in detail and existing data are reviewed. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:105 / 112
页数:8
相关论文
共 50 条
  • [31] Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
    Massani, Marco
    Stecca, Tommaso
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Janssen, Quisette P.
    O'Reilly, Eileen M.
    Van Eijck, Casper H. J.
    Groot Koerkamp, Bas
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [33] Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer
    Scheufele, F.
    Friess, H.
    CHIRURG, 2020, 91 (05): : 391 - 395
  • [34] Borderline resectable pancreatic cancer: an evolving concept
    Petrucciani, N.
    Debs, T.
    Nigri, G.
    D'Angelo, F.
    Gugenheim, J.
    Ramacciato, G.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2315 - 2315
  • [35] Defining and Treating Borderline Resectable Pancreatic Cancer
    Giampaolo Perri
    Laura Prakash
    Matthew H. G. Katz
    Current Treatment Options in Oncology, 2020, 21
  • [36] Aggressive Surgery for Borderline Resectable Pancreatic Cancer
    Yamada, Suguru
    Fujii, Tsutomu
    Sugimoto, Hiroyuki
    Nomoto, Shuji
    Takeda, Shin
    Kodera, Yasuhiro
    Nakao, Akimasa
    PANCREAS, 2013, 42 (06) : 1004 - 1010
  • [37] Borderline resectable pancreatic cancer: Certainties and controversies
    Nappo, Gennaro
    Donisi, Greta
    Zerbi, Alessandro
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2021, 13 (06): : 516 - 528
  • [38] Perioperative treatments for borderline resectable pancreatic cancer
    Takahashi, Shinichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S265 - S265
  • [39] Borderline Resectable Pancreatic Cancer: Challenges for Clinical
    Fawaz, Ali
    Abdel-Rahman, Omar
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3589 - 3598
  • [40] Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
    Barreto, Savio George
    Shrikhande, Shailesh, V
    Sirohi, Bhawna
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2024, 15 (SUPPL 2) : 249 - 254